Diagnostic endoscopic procedures on the upper gastrointestinal tract
Ask the expert
The report presents a summary of reimbursement situation for diagnostic endoscopic procedures on the upper gastrointestinal tract for benign and malignant diseases in outpatient settings.
The following procedures will be considered:
The report will consider both stand-alone diagnostic procedures and in combination with biopsy of lesions.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of endoscope equipment for the upper gastrointestinal tract include:
- Alltion (Fiber-GIS)
- Aohua Ednoscopy (FHD-GT, VGT, VME)
- Cogentix Medical (PrimeSight)
- Cook Medical (Shooter Saeed, Shooter Universal Saeed)
- Endomed Systems (Duo, Combo-2)
- Fujifilm Holdings Corporation (Eluxeo EG, ED)
- Huger Endoscopy System (GVE)
- Interscope (EndoRotor)
- IntroMedic (E.G. Scan)
- KARL STORZ GmbH & Co. KG (Silver Scope, Tele Pack X)
- Olympus (EVIS EXERA-Gif)
- Pentax medical (MagniView EG, Transnasal EG, G-EYE)
- SonoScape (EG-330 series)
- Stryker Corporation (1588 AIM)
Table of content is not available at the moment. Report is still ongoing.
In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.Read more
In March 2021, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids, extracorporeal whole liver perfusion, free-functioning gracilis transfer to restore upper limb function, cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy), two Medical Technologies Guidance (Danis stent for acute oesophageal variceal bleeding, Alpha-Stim AID for anxiety disorders), two Medtech Innovation Briefings (Sonata system for symptomatic uterine fibroids, Butterfly iQ+ for diagnostic ultrasound), and one Diagnostic Guidance (QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis). Also, five clinical guidelines were updated.Read more
In January 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0174 and 0071 with changes to be implemented not later than May 01, 2021. Five new procedure codes related to the areas of men's health, robotic surgery, endoscopy, and orthopedics, as well as three new diagnostic codes, were introduced.Read more
In November 2020, the Clinical Coding and Schedule Development (CCSD) group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0173 and 0070 with changes to be implemented not later than February 01, 2021. Three new procedure codes were introduced, related to robotic laparoscopy in gynecology, brachytherapy in prostate tumor, and autologous bone marrow aspirate concentrate (BMAC) for osteochondral defects of the knee. Also, four codes for diagnostic tests were added.Read more
In Sensible Care projects, the Dutch Healthcare Institute, together with other parties, is investigating the possibilities for improving care pathways for patients. As of early November 2020, there are 30 ongoing projects, including two projects for assessing knee and hip osteoarthritis treatment and medicines for castration-refractory prostate carcinoma at the final evaluation phase.Read more